HLN | Haleon plc Stock Overview

(Stock Exchange: NYSE)

Day's Range	9.74 - 9.86
52 Week Range	7.89 - 10.80
Beta	0.31
Implied Volatility	53.70%
IV Rank	33.95%
Day's Volume	4,429,697
Average Volume	5,111,682
Shares Outstanding	4,557,197,750
Market Cap	44,478,250,040
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic
IPO Date	2022-07-25

Valuation
Profitability
Growth
Health
P/E Ratio	28.71
Forward P/E Ratio	N/A
EPS	0.34
1YR Price Target	N/A
Dividend Yield	1.06%
Dividend Per Share	0.10
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	25,408
Country	UK
Website	HLN

Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was incorporated in 2021 and is headquartered in Brentford, the United Kingdom.

HLN's peers: BHC, ELAN, KD, TAK, TEVA, VTRS, ZTS, RDY, EBS, HCM, PETQ, NBIX, CTLT, LNTH, SIGA, INVVY, ESPR

*Chart delayed

Analyzing fundamentals for HLN we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is bad and Health is weak. For more detailed analysis please see HLN Fundamentals page.

Watching at HLN technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, but short-term trend is bearish. More technicals details can be found on HLN Technicals page.